Myelofibrosis Therapeutics Pipeline Analysis, 2017

  • ID: 4435241
  • Report
  • 130 pages
  • P&S Market Research
1 of 3
Myelofibrosis Therapeutics Pipeline in 2017

The study analysed that the therapeutics pipeline comprises of approximately 29 drug candidates in different stages of development. Myelofibrosis is a rare disorder in which excessive scar tissue gets formed in the bone marrow that impairs its ability to produce red blood cells. However, it is believed by researchers that myelofibrosis occurs due to the presence of abnormal red blood stem cells in the bone marrow. The abnormal blood stem cells produce mature cells that grow quickly and form scar tissue which leads to chronic inflammation.

Strategic Collaborations for the Development of Myelofibrosis Therapeutics

Various companies, educational institutes and medical organization are collaborating for the development of therapeutics for the treatment of myelofibrosis. For instance, Geron Corporation and Janssen Pharmaceuticals, Inc. entered into a collaboration agreement, in which Geron Corporation granted an exclusive worldwide right to Janssen, for the development and commercialization of imetelstat for all human therapeutic uses, including hematologic myeloid malignancies.

Various drug candidates are being developed as small molecule

According to the research, there are several companies having drug candidates in their pipeline, using synthetic sources for the development of drugs for the treatment of myelofibrosis. Imetelstat is an oligonucleotide obtained from synthetic source that acts as telomerase inhibitor.

Some of the key players developing drugs for myelofibrosis include CTI BioPharma Corporation, Geron Corporation, Gilead Sciences, Inc. and others.
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1. Research Objectives
1.2. Definition
1.3. Research Scope
1.3.1. Pipeline Analysis by Phase
1.3.2. Pipeline Analysis by Route of Administration
1.3.3. Pipeline Analysis by Molecule Type
1.4. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents By industry participants By company type

3. Executive Summary

4. Pipeline Outlook
4.1. Overview
4.1.1. Signs and Symptoms
4.1.2. PAThophysiology
4.1.3. Diagnosis
4.1.4. Treatment
4.1.5. Epidemiology
4.2. Key Drivers
4.3. Key Barriers
4.4. Pipeline Analysis
4.4.1. Pipeline Analysis by Phase
4.4.2. Pipeline Analysis by Molecule Type
4.4.3. Pipeline Analysis by Route of Administration
4.4.4. Pipeline Analysis by Company

5. Pipeline Analysis by Phase
5.1. Pre-registration/Registration: Drug Profiles
5.1.1. Pre-Clinical Studies
5.1.2. Clinical Trials
5.1.3. Clinical Results
5.1.4. Strategic Developments
5.1.5. Designations
5.1.6. Grants
5.1.7. Patents
5.1.8. Technology
5.2. Phase III: Drug Profiles
5.2.1. Pre-Clinical Studies
5.2.2. Clinical Trials
5.2.3. Clinical Results
5.2.4. Strategic Developments
5.2.5. Designations
5.2.6. Grants
5.2.7. Patents
5.2.8. Technology
5.3. Phase II: Drug Profiles
5.3.1. Pre-Clinical Studies
5.3.2. Clinical Trials
5.3.3. Clinical Results
5.3.4. Strategic Development
5.3.5. Designations
5.3.6. Grants
5.3.7. Patents
5.3.8. Technology
5.4. Phase I: Drug Profiles
5.4.1. Pre-Clinical Studies
5.4.2. Clinical Trials
5.4.3. Clinical Results
5.4.4. Strategic Developments
5.4.5. Designations5.4.6. Grants
5.4.7. Patents
5.4.8. Technology
5.5. Pre-Clinical: Drug Profiles
5.5.1. Pre-Clinical Studies
5.5.2. Strategic Developments
5.5.3. Designations
5.5.4. Grants
5.5.5. Patents5.5.6. Technology
5.6. Discovery: Drug Profiles
5.6.1. Strategic Developments
5.6.2. Designations
5.6.3. Grants
5.6.4. Patents
5.6.5. Technology
5.7. Inactive: Drug Profiles
5.7.1. Pre-Clinical Studies
5.7.2. Clinical Trials
5.7.3. Clinical Results
5.7.4. Strategic Developments
5.7.5. Designations
5.7.6. Grants
5.7.7. Patents
5.7.8. Technology5.8. Discontinued: Drug Profiles
5.8.1. Pre-Clinical Studies
5.8.2. Clinical Trials
5.8.3. Clinical Results
5.8.4. Strategic Developments
5.8.5. Designations
5.8.6. Grants
5.8.7. Patents
5.8.8. Technology

6. Clinical Trials Analysis
6.1. Clinical Trials by Region
6.2. Clinical Trials by Trial Status

7. Competitive Landscape Analysis
7.1. Key Players Benchmarking
7.2. SWOT Analysis

8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations

Note: Certain sections of the above table of contents would vary according to the availability of information.
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown